Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men.

  title={Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men.},
  author={Lukas P. Degen and Juergen Drewe and Franziska Piccoli and Karin Gr{\"a}ni and Sibylle Oesch and Raluca Bunea and Massimo D'Amato and Christoph Beglinger},
  journal={American journal of physiology. Regulatory, integrative and comparative physiology},
  volume={292 4},
  • L. DegenJ. Drewe C. Beglinger
  • Published 1 April 2007
  • Biology
  • American journal of physiology. Regulatory, integrative and comparative physiology
Cholecystokinin (CCK), peptide YY (PYY), and ghrelin have been proposed to act as satiety hormones. CCK and PYY are stimulated during meal intake by the presence of nutrients in the small intestine, especially fat, whereas ghrelin is inhibited by eating. The sequence of events (fat intake followed by fat hydrolysis and CCK release) suggests that this process is crucial for triggering the effects. The aim of this study was therefore to investigate whether CCK mediated the effect of intraduodenal… 

Figures from this paper

Regulation of fat-stimulated neurotensin secretion in healthy subjects.

Generation of C18 through hydrolysis of fat is a critical step for fat-induced stimulation of neurotensin in humans; the signal is in part mediated via CCK release and CCK-1 receptors.

Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion.

Generation of long-chain fatty acids through hydrolysis of fat is a critical step for fat-induced stimulation of GLP-1 in humans; the signal is mediated via CCK release and CCK-1 receptors.

Dose-dependent effects of cholecystokinin-8 on antropyloroduodenal motility, gastrointestinal hormones, appetite, and energy intake in healthy men.

It is demonstrated that exogenous CCK-8 has dose-related effects on APD motility, plasma PYY, desire to eat, and energy intake and suggests that the suppression of energy intake is related to the stimulation of IPPW.

Sulfated cholecystokinin-8 increases ghrelin secretion but does not affect oxyntomodulin in Holstein steers.

It is shown for the first time, that intravenous bolus injection of CCK increased ghrelin secretion in ruminants and Ghrelin did not affect the secretions of CCk and OXM.

Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Gastric emptying, the detection of specific digestive products by small intestinal enteroendocrine cells, and synergistic interactions among different GI loci all contribute to the secretion of ghrelin, CCK, GLP-1, and PYY(3-36).

Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects.

  • F. EncT. Ones N. Imeryüz
  • Medicine
    American journal of physiology. Gastrointestinal and liver physiology
  • 2009
Orlistat administered similar to its use in obesity treatment accelerates gastric emptying of a solid mixed meal with a moderate energy load and profoundly attenuates release of GIP without appreciably altering plasma responses of CCK, GLP-1, and PP.

Thylakoids promote release of the satiety hormone cholecystokinin while reducing insulin in healthy humans

The addition of thylakoids to energy-dense food promotes satiety signals and reduces insulin response during a single meal in man.

Orlistat and the Influence on Appetite Signals

These alterations in gastrointestinal hormone concentrations can cause increased appetite sensations and greater food consumption and may therefore counteract the weight-lowering effect of orlistat.

A high-fat diet raises fasting plasma CCK but does not affect upper gut motility, PYY, and ghrelin, or energy intake during CCK-8 infusion in lean men.

In humans, the effects of exogenous CCK-8 on antropyloroduodenal motility, plasma CCK, peptide YY (PYY), and ghrelin concentrations, appetite, and energy intake are attenuated by a high-fat diet.

Integrating GHS into the Ghrelin System

Oligopeptide derivatives of metenkephalin were found to stimulate growth-hormone (GH) release directly by pituitary somatotrope cells in vitro in 1977. Members of this class of peptides and



Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid.

In healthy humans, in healthy young males, the presence of fat in the small intestine suppresses ghrelin secretion, and fat-induced suppression of gh Relin and stimulation of PYY and PP is dependent on fat digestion.

Interaction between CCK and a preload on reduction of food intake is mediated by CCK-A receptors in humans.

CCK-8 interacts with an appetizer to modulate satiety in humans and these effects are mediated by CCK-A receptors, which are antagonized for hunger and fullness by loxiglumide.

Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans.

In conclusion, lipase inhibition attenuates the effects of duodenal fat on antropyloroduodanal motility, appetite, and CCK and glucagon-like peptide-1 secretion.

The role of long chain fatty acids in regulating food intake and cholecystokinin release in humans

Generation of long chain fatty acids through hydrolysis of fat is a critical step for fat induced inhibition of food intake; the signal is mediated via CCK-A receptors.

Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men.

CCK and GLP-1 are meal-related satiety signals that are released from the gastrointestinal tract during food intake that reject the hypothesis that the two peptides exert a positive synergistic effect on food intake compared with the effects observed with infusion of individual peptides.

Inhibition of food intake in obese subjects by peptide YY3-36.

It is found that obese subjects were not resistant to the anorectic effects of PYY, and endogenous PYY levels were low in obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.

Cholecystokinin and peptide YY are released by fat in either proximal or distal small intestine in dogs

CCK1 Antagonists: Are They Ready for Clinical Use?

Important inroads have been made in the potential role of these CCK1 antagonists in the treatment of GERD, IBS and pancreatitis and they have also shown encouraging results in sphincter of Oddi dysfunction and some gastrointestinal cancers.